EOM 1352: Fri 7 June 2024, 11:36
Catalyst 7 July 2023, 14:52

Current Edition

Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Europe

Anavex Life Sciences Receives Approval To Initiate Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s Disease

ANAVEX®2-73 Being Studied as Potential First Precision Medicine Biomarker-guided, Targeted Therapeutic in Alzheimer’s Disease Primary and Secondary Endpoints mea...
Continue Reading →
Catalyst: Fri 8 November 2024, 14:16
Biosynth: Wed 13 November 2024, 10:18